AbbVie is past the worst of Humira biosimilar erosion with Skyrizi and Rinvoq combined trajectory above $24B by 2027. Cerevel and ImmunoGen acquisitions add neuroscience and oncology. Aesthetics business stable. Capital allocation disciplined with steady dividend growth. Re-rating possible as biosimilar cliff fades from narrative.
Thesis reviewed May 29, 2026
AbbVie Inc. is headquartered in United States, which is currently showing elevated risk signals.
🇺🇸United States82EXITView United States risk detail →💊Pharma0NEUTRAL| Ticker | Company | Score | Gap | Signal Δ | Action |
|---|---|---|---|---|---|
| AZN | AstraZeneca PLC | 50 | +11% | ↓0% | EARLY |
| JNJ | Johnson & Johnson | 50 | +8% | ↓0% | NEUTRAL |
| REGN | Regeneron Pharmaceuticals Inc. | 50 | -16% | ↓0% | AVOID |
| TAK | Takeda Pharmaceutical Company Limited | 50 | +10% | ↓0% | NEUTRAL |
| LLY | Eli Lilly and Company | 50 | +24% | ↓0% | EARLY |
| PFE | Pfizer Inc. | 50 | +6% | ↓0% | NEUTRAL |
| NVO | Novo Nordisk A/S | 50 | +15% | ↓0% | EARLY |
Investors who hold ABBV may also have indirect exposure through these country funds.
Skyrizi/Rinvoq combined sales exceed Humira peak
Cerevel emraclidine Phase 3 data positive
Estimates · Yahoo Finance · Not audited figures
| Politician | Party | Type | Amount | Trade Date | Return |
|---|---|---|---|---|---|
| Alan Armstrong | Buy | $15k–$50k | Mar 27, 26 | ||
| Josh GottheimerNJ | Buy | $1k–$15k | May 5, 26 | ||
| Donald J. TrumpFL | R | Buy | $50k–$50k | Mar 11, 26 | +4.4% |
| Julie JohnsonTX | D | Buy | $1k–$15k | Dec 18, 25 | +2.1% |
| Julia LetlowLA | R | Buy | $1k–$15k | Apr 28, 25 | +0.2% |
| Julia LetlowLA | R | Buy | $1k–$15k | Jan 24, 25 | +0.2% |
| Julia LetlowLA | R | Buy | $1k–$15k | Dec 8, 25 | +0.2% |
| Julia LetlowLA | R | Buy | $1k–$15k | Oct 23, 24 | +0.2% |
| John Boozman | Sell | $1k–$15k | Aug 11, 25 | +2.1% | |
| John Boozman | Sell | $1k–$15k | Aug 22, 25 | +2.1% | |
| Marjorie Taylor Mrs GreeneGA | R | Buy | $1k–$15k | Nov 20, 24 | +33.4% |
| John JamesMI | R | Buy | $1k–$15k | Sep 4, 24 | +19.4% |
| John JamesMI | R | Buy | $1k–$15k | Nov 10, 23 | +17.6% |
| Kathy ManningNC | Buy | $1k–$15k | Jul 2, 24 | +19.1% |